Results 61 to 70 of about 9,286 (149)

PE-005 Análise de Custo-Minimização entre Ganciclovir e Valganciclovir para o Tratamento Preemptivo e Profilaxia de Infecções por Citomegalovírus em Transplantados

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução (com objetivo): O citomegalovírus (CMV) é um herpesvírus humano de relevância clínica em pacientes submetidos a transplantes de órgãos sólidos (TOS) e de células-tronco hematopoéticas (TCTH)(1). Em pacientes imunossuprimidos, infecções por CVM
Danielle Bezerra Santana, Alonso Barros da Silva Junior, Maria Erivanda Castelo Meireles, Gilberto Alexandre Barbosa Moura, Amanda Maria Paixão Soares   +4 more
doaj   +2 more sources

Hidrops fetal por infección congénita por citomegalovirus: tratamiento posneonatal prolongado con valganciclovir

Revista Chilena de Obstetricia y Ginecología, 2012
El citomegalovirus (CMV) es la infección viral congénita más frecuente con una prevalencia de 0,5% al nacimiento. La primoinfección aparece entre el 1-4% de las gestantes seronegativas.
Silvia Campos Arca, María Fernández Rial, Isabel Pardo Pumar, Cristina Luaces, José García Piñó, Eloy Moral Santamarina   +5 more
doaj  

Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand

Journal of Pharmaceutical Policy and Practice
Background Cytomegalovirus retinitis (CMVR) is an opportunistic infection frequently seen in people living with HIV (PLHIV) and can cause blindness. Intravenous (IV) ganciclovir is a typical CMVR treatment in Thailand, but oral valganciclovir is a more ...
Tippawan Wongwian, Jatapat Hemapanpairoa, Nattanichcha Kulthanachairojana   +2 more
doaj   +1 more source

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis

Journal of Research in Medical Sciences, 2014
Background: Cytomegalovirus (CMV), a problematic virus in solid organ transplant recipients (SOTR) such as liver, can worsen overall mortality and transplant outcome, so its prevention and treatment is a key of success in such patients.
Siavash Vaziri, Zohre Pezhman, Babak Sayyad, Feizolla Mansouri, Alireza Janbakhsh, Mandana Afsharian, Farid Najafi   +6 more
doaj  

Abstracts from the 2026 Congress of the Scandinavian Society of Anesthesiology and Intensive Care Medicine, Reykjavik, Iceland, June 10–12, 2026

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 9, October 2026.
wiley   +1 more source

Comprehensive insights into cytomegalovirus anterior segment infections: A narrative review

Taiwan Journal of Ophthalmology
Cytomegalovirus (CMV) anterior uveitis (AU), a significant cause of intraocular inflammation, is increasingly recognized in immunocompetent individuals, often leading to visual morbidity if not promptly addressed.
Yih-Shiou Hwang, Po-Yi Wu, Eugene Yu-Chuan Kang, Wei-Chi Wu, Linda Yi-Hsing Chen, Chi-Chun Lai, Kyung Seek Choi   +6 more
doaj   +1 more source

Valacyclovir versus valganciclovir for cytomegalovirus prophylaxis in kidney transplant recipients: a systematic review and comparative meta-analysis

Clinical Transplantation and Research
Background : Valganciclovir (ValG) is the most widely used drug for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients (KTRs). However, it is associated with dose-limiting side effects and considerable costs.
Leonardo Januário Campos Cardoso, Kleuber Arias Meireles Martins, Paulo Vitor Marques, Ivan Petterson Santana Teixeira, Ester Magalhães, Juan Lima Minkauskas, Isabela Coutinho Faria, Filipe Melo Ribeiro   +7 more
doaj   +1 more source

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease

Clinical Pharmacology: Advances and Applications, 2009
Heather E Vezina1,2, Richard C Brundage2, Thomas E Nevins3, Henry H Balfour Jr1,31Department of Laboratory Medicine and Pathology, 2Department of Experimental and Clinical Pharmacology, 3Department of Pediatrics, University of ...
Heather E Vezina, Richard C Brundage, Thomas E Nevins, et al   +3 more
doaj  

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

Infection and Drug Resistance, 2019
Guy El Helou,1,2 Raymund R Razonable1,21Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USAAbstract ...
El Helou G, Razonable RR
doaj  

Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients Aged 65 y or Older: Findings From a Randomized, Phase 3 Trial. [PDF]

Transplant Direct
Bunnapradist S, Vincenti F, Witzke O, Schneeberger S, Nguyen MH, Broyde N, Gilbert CL, Haber B.   +7 more
europepmc   +1 more source